Copanlisib in Solid Tumors or Lymphoma

Visit Criteria

This study will enroll male and female patients between 6 months and 21 years of age with histologic verification of a solid tumor or lymphoma malignancy at diagnosis for which there is no standard curative anti-cancer treatment or treatment is no longer effective and must have received at least one prior line of therapy. Copanlisib will be given via IV infusion on days 1, 8, and 15 of each 28-day cycle. Study visits will also include the following assessments: tissue submission, blood samples to measure chemistries, blood clotting, screen for infection, and to assess how the body handles the drug (pharmacokinetic studies), ECG, echocardiogram, and study drug administration. In addition to the study visits, subjects will need to come to CHOP frequently for assessments as part of regular cancer care. This includes follow-up visits, blood draws, and scans to monitor any side effects and tumor response.